전립선암 치료제 시장 : 치료 메커니즘, 치료 단계, 제형, 유통 채널, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Prostate Cancer Therapeutics Market is projected to grow by USD 17.59 billion at a CAGR of 6.64% by 2032.

Prostate cancer therapeutics are moving from a historically hormone-centered category toward a precision oncology model that combines androgen deprivation therapy, androgen receptor pathway inhibitors, taxanes, PARP inhibitors, PSMA-targeted radiopharmaceuticals, immunotherapy for selected biomarker-defined patients, and supportive bone-targeted care. The clinical need remains substantial: GLOBOCAN 2022 estimated more than 1.46 million new prostate cancer cases and approximately 397,000 deaths worldwide, making prostate cancer one of the most frequently diagnosed cancers in men.

Market momentum is being shaped by earlier treatment intensification, improved genomic testing, expanded PSMA PET imaging, and broader use of therapies across metastatic hormone-sensitive prostate cancer, non-metastatic castration-resistant prostate cancer, and metastatic castration-resistant prostate cancer. For industry stakeholders, the competitive frontier is increasingly defined by survival benefit, tolerability, sequencing evidence, real-world outcomes, diagnostic infrastructure, and payer confidence in high-value innovation.

Transformative Shifts in the Prostate Cancer Treatment Landscape

The prostate cancer treatment landscape is being reshaped by the migration of advanced therapies into earlier lines of care. Treatment intensification with androgen receptor pathway inhibitors in metastatic hormone-sensitive disease has changed standard practice, while non-metastatic castration-resistant prostate cancer has become a key setting for delaying metastasis and extending survival.

Precision medicine is another defining shift. Regulatory approvals for PARP inhibitors in selected patients with homologous recombination repair alterations and PSMA-targeted radioligand therapy for eligible metastatic castration-resistant disease have established biomarker-enabled treatment as a major clinical and commercial driver. At the same time, demand for PSMA PET imaging, next-generation sequencing, liquid biopsy, and multidisciplinary treatment pathways is increasing the strategic value of diagnostics partnerships and integrated care models.

Cumulative Impact of Artificial Intelligence in Prostate Cancer Therapeutics

Artificial intelligence is becoming a cumulative enabler across prostate cancer therapeutics, not a single-point disruption. In discovery and translational research, AI supports target prioritization, molecular pattern recognition, and trial enrichment by analyzing genomic, imaging, pathology, and clinical datasets. These capabilities can help developers identify responsive subpopulations and reduce the risk of underpowered or poorly selected trials.

In clinical practice, AI-assisted pathology and radiology may improve risk stratification, lesion detection, and treatment planning when validated against rigorous clinical standards. In commercialization, AI-driven real-world evidence analytics can help manufacturers understand treatment sequencing, adherence, toxicity patterns, and health equity gaps. The strongest opportunity lies in responsibly governed AI systems that improve decision support while protecting patient privacy, reducing bias, and aligning with regulatory expectations.

Key Regional Insights: Global Adoption Patterns

Asia-Pacific is expanding as China, Japan, South Korea, India, and Australia strengthen oncology infrastructure, broaden access to advanced imaging, and increase adoption of novel hormonal agents. Japan, South Korea, and Australia benefit from mature reimbursement and specialist networks, while China is scaling cancer care capacity and India is improving access through large tertiary oncology centers despite affordability constraints. North America remains a leading innovation and reimbursement region, supported by high disease awareness, advanced diagnostics, academic trial networks, and regulatory approvals for radioligand and biomarker-directed therapies.

Latin America shows growing demand but uneven access, with Brazil and Mexico acting as important treatment hubs while reimbursement constraints and fragmented health coverage influence uptake of premium therapies. Europe benefits from strong guideline adoption, cancer registries, multidisciplinary urology-oncology care, and expanding PSMA PET and genomic testing capabilities, although pricing, procurement, and health technology assessment requirements vary by country.

The Middle East, led by Gulf health system investment, is increasing access to oncology centers, nuclear medicine capacity, and specialty care for advanced prostate cancer. Africa continues to face underdiagnosis, late presentation, and limited access to advanced therapeutics in many markets, making diagnostic capacity, workforce training, pathology services, radiotherapy availability, and affordable treatment pathways essential to long-term development.

Key Group Insights: Strategic Market Clusters

ASEAN markets are gaining relevance as urban oncology centers expand access to hormonal therapies, imaging, and specialist care, though reimbursement variation remains a barrier to consistent adoption of advanced prostate cancer therapeutics. The GCC is positioned for faster uptake due to investment in specialty hospitals, nuclear medicine infrastructure, digital health programs, and national cancer strategies that support earlier diagnosis and centralized cancer care.

The European Union remains central to evidence-based adoption because centralized regulatory review is followed by country-level health technology assessment, reimbursement decisions, and pricing negotiations. BRICS countries represent a significant treatment-access opportunity, combining large patient populations with policy efforts to localize manufacturing, expand cancer services, strengthen screening awareness, and improve availability of innovative oncology medicines.

G7 countries continue to influence clinical guidelines, pricing benchmarks, regulatory standards, real-world evidence expectations, and adoption of precision oncology tools such as genomic testing and PSMA PET imaging. NATO members overlap substantially with North American and European high-income markets, where supply chain resilience, radiopharmaceutical logistics, isotope access, cybersecurity, and secure health data infrastructure are becoming increasingly relevant to oncology care continuity.

Key Country Insights: Priority Prostate Cancer Markets

The United States anchors global prostate cancer therapeutics innovation, with the American Cancer Society estimating about 299,010 new prostate cancer cases and 35,250 deaths in 2024, supported by broad access to clinical trials, advanced imaging, genomic testing, and specialty oncology care. Canada benefits from organized cancer systems and growing precision oncology adoption, while Mexico and Brazil show rising demand amid unequal access across public and private health systems and increasing reliance on major urban oncology centers.

The United Kingdom, Germany, France, Italy, and Spain are influential European markets shaped by guideline-driven care, national reimbursement decisions, multidisciplinary cancer networks, and expanding use of advanced diagnostics. Germany and France maintain strong oncology infrastructure, the United Kingdom emphasizes evidence-based access through national assessment pathways, and Italy and Spain continue to advance specialist care delivery across regional health systems. Russia remains a sizable market by population but faces access, reimbursement, and supply considerations that influence adoption of newer prostate cancer agents.

China is scaling oncology access, genomic medicine, nuclear medicine capacity, and domestic innovation, while India has high long-term treatment need but significant affordability and access constraints outside leading metropolitan cancer centers. Japan maintains strong adoption of advanced therapies under a structured reimbursement system, Australia offers mature cancer care and active clinical trial participation, and South Korea combines advanced diagnostics, digital health capability, and a competitive biopharmaceutical ecosystem to support precision prostate cancer treatment.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence generation that demonstrates overall survival, radiographic progression-free survival, quality of life, safety, and real-world value across clearly defined prostate cancer patient segments. Organizations that integrate companion diagnostics, PSMA imaging pathways, and genomic testing support into commercialization plans will be better positioned to capture biomarker-driven demand.

Strategic focus should also include treatment sequencing research, radiopharmaceutical supply chain resilience, isotope availability planning, referral pathway optimization, and differentiated patient support programs. In cost-sensitive markets, tiered access models, local partnerships, physician education, and health economic evidence will be critical for sustainable growth in prostate cancer therapeutics.

Research Methodology

This executive summary is developed through triangulation of publicly available epidemiology, regulatory, clinical, and market-access sources. Core references include global cancer burden estimates, national cancer statistics, regulatory approvals, clinical guideline trends, peer-reviewed trial evidence, oncology infrastructure indicators, and publicly available health system information.

The analysis emphasizes verified disease burden, approved therapeutic classes, observable adoption drivers, documented infrastructure trends, and evidence-based access considerations. Insights are synthesized to support strategic decision-making across pharmaceutical development, diagnostics integration, regional access planning, and competitive positioning in prostate cancer therapeutics, while avoiding market sizing, market share estimation, and forecasting.

Conclusion

The prostate cancer therapeutics category is entering a new era defined by precision treatment, earlier intensification, PSMA-targeted radioligand innovation, and data-enabled care delivery. While high-income markets lead adoption of advanced agents, the largest long-term opportunities will come from improving diagnosis, genomic testing, imaging access, affordability, and treatment continuity across emerging regions.

Organizations that combine differentiated clinical evidence with diagnostic integration, AI-enabled real-world insights, radiopharmaceutical readiness, and regionally tailored access strategies will be best positioned to compete in this evolving oncology category.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Prostate Cancer Therapeutics Market, by Therapeutic Mechanism

• 7.1. Chemotherapy
  • 7.1.1. Platinum Compounds
  • 7.1.2. Taxanes
• 7.2. Hormone Therapy
  • 7.2.1. Antiandrogens
  • 7.2.2. CYP17 Inhibitors
  • 7.2.3. GnRH Agonists
  • 7.2.4. GnRH Antagonists
• 7.3. Immunotherapy
  • 7.3.1. Cancer Vaccines
  • 7.3.2. Cell Therapy
  • 7.3.3. Checkpoint Inhibitors
• 7.4. Radiopharmaceuticals
  • 7.4.1. Alpha Emitters
  • 7.4.2. Beta Emitters
• 7.5. Targeted Therapy
  • 7.5.1. Monoclonal Antibodies
  • 7.5.2. Parp Inhibitors
  • 7.5.3. Tyrosine Kinase Inhibitors

8. Prostate Cancer Therapeutics Market, by Therapy Line

• 8.1. First Line
• 8.2. Second Line
• 8.3. Third Line & Beyond

9. Prostate Cancer Therapeutics Market, by Formulation

• 9.1. Injectable
• 9.2. Oral

10. Prostate Cancer Therapeutics Market, by Distribution Channel

• 10.1. Hospital Pharmacies
• 10.2. Online Pharmacies
• 10.3. Retail Pharmacies

11. Prostate Cancer Therapeutics Market, by End User

• 11.1. Cancer Centers
• 11.2. Homecare Providers
• 11.3. Hospitals
• 11.4. Specialty Clinics

12. Prostate Cancer Therapeutics Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Prostate Cancer Therapeutics Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Prostate Cancer Therapeutics Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. AbbVie Inc.
• 16.2. Amgen Inc.
• 16.3. Astellas Pharma Inc.
• 16.4. AstraZeneca PLC
• 16.5. Bayer AG
• 16.6. Bristol-Myers Squibb Company
• 16.7. Eisai Inc.
• 16.8. Eli Lilly and Company
• 16.9. F. Hoffmann-La Roche AG
• 16.10. Genentech, Inc.
• 16.11. GlaxoSmithKline plc
• 16.12. Ipsen S.A.
• 16.13. Johnson & Johnson Services Inc.
• 16.14. Merck & Co., Inc.
• 16.15. Novartis AG
• 16.16. Pfizer Inc.
• 16.17. Sanofi S.A.
• 16.18. Takeda Pharmaceutical Company Limited
• 16.19. Teva Pharmaceutical Industries Ltd.